Program Description
Acute myeloid leukemia (AML) is a rapidly progressing hematologic cancer that primarily affects older adults. Approximately 50% of all patients with AML who achieve a first remission will eventually relapse, and this rate is significantly higher in older adults, as many are unable to tolerate the intensive chemotherapy and consolidation therapy strategies. In recent years, the treatment landscape has transitioned from “7+3” chemotherapy to a complex landscape of molecularly targeted therapies, driven by molecular markers. The rapid approval of targeted agents such as FLT3, IDH1/2, and menin inhibitors has transformed AML into a disease managed as much in the home as in the clinic. Yet, this approach has also introduced significant challenges surrounding next-generation sequencing results, adverse effect management, and appropriate medication use. This webinar will explore the pathophysiology of AML, with a focus on how menin inhibitors may be integrated into treatment regimens based on clinical trial data in the frontline, relapsed/refractory, and posttransplant AML settings. Expert faculty will discuss strategies to prevent and manage adverse effects associated with menin inhibitors. Best practices for supporting the multidisciplinary team, sharing patient education, and implementing community oncology pharmacy logistics will also be presented.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: March 5, 2026
Expiration date: May 5, 2026
Time to complete activity: 1.25 hour
Learner level: Foundational, Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explain the mechanism of action of menin inhibitors and the therapeutic rationale in acute myeloid leukemia (AML)
- Evaluate pivotal efficacy and safety data of commercially available and investigational menin inhibitors from clinical trials in AML
- Identify strategies for monitoring and managing adverse effects associated with commercially available and investigational menin inhibitors for the treatment of AML
- Develop pharmacist-led strategies for integrating menin inhibitors into AML care pathways, with attention to sequencing, adherence, and supportive care
Anthony J. Perissinotti, PharmD, BCOP
Hematology Clinical Pharmacist Specialist
University of Michigan
Ann Arbor, MI
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number TBD. The activity is available for CE credit through May 5, 2026.
Instructions for Completing the Activity and Receiving CPE Credit
To
receive CPE credit, participants must complete the pretest, review the activity in
its entirety, complete the posttest, and complete the online activity
evaluation. After successful completion of the online activity evaluation, you
can submit your credit to CPE Monitor. You may view your credit within 48 hours
at www.mycpemonitor.net. All participants must request credit before the
activity expiration date. CE credit will not be issued after this date.
Disclosures
Anthony J. Perissinotti, PharmD, BCOP, has no relevant financial relationships with ineligible companies to disclose.
Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine,
RPh, MBA; Jason Christidhis, PharmD; Victoria Chirdo; Susan
Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships
with ineligible companies to disclose.
At least one anonymous peer reviewer has
been used as part of content validation and conflict resolution. The peer
reviewer has no relevant financial relationships with ineligible companies to
disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not
constitute any form of professional advice or referral. Discussions concerning
drugs, dosages, and procedures may reflect the clinical experience of the
author(s) or they may be derived from the professional literature or other
sources and may suggest uses that are investigational in nature and not
approved labeling or indications. Participants are encouraged to refer to primary
references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms